Login Register Cart 0
Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Thrombopoietin Receptor Agonists in Children with Immune Thrombocytopenia: A New Therapeutic Era

Author(s): Giuseppe Lassandro, Valentina Palladino, Giovanni C.D. Vecchio, Viviana V. Palmieri, Paola C. Corallo, Maria F. Faienza and Paola Giordano*

Volume 21, Issue 3, 2021

Published on: 31 May, 2020

Page: [397 - 406] Pages: 10

DOI: 10.2174/1871530320666200531142244

Price: $65

conference banner
Abstract

Background and objective: Immune thrombocytopenia (ITP) is a common bleeding disorder in childhood. The management of ITP in children is controversial, requiring personalized assessment of patients and therapeutic choices. Thrombopoietin receptor agonists (TPO-RAs), eltrombopag and romiplostim, have been shown to be safe and effective for the treatment of pediatric ITP. The aim of our research is to define the role of thrombopoietin receptor agonists in the management of pediatric ITP.

Methods: This review focuses on the use of TPO-RAs in pediatric ITP, in randomized trials and in clinical routine, highlighting their key role in the management of the disease.

Results: Eltrombopag and romiplostim appear effective treatment options for children with ITP. Several clinical studies have assessed that the use of TPO-RAs increases platelet count, decreases bleeding symptoms and improves health-related quality of life. Moreover, TPO-RAs are well tolerated with minor side effects.

Conclusion: Although long term efficacy and safety of TPO-RAs still require further investigations, their use is gradually expanding in the clinical practice of children with ITP.

Keywords: Eltrombopag, children, immune thrombocytopenia, thrombopoietin receptor agonists, romiplostim, platelets.

« Previous Next »
Graphical Abstract

[1]
Rodeghiero, F.; Stasi, R.; Gernsheimer, T.; Michel, M.; Provan, D.; Arnold, D.M.; Bussel, J.B.; Cines, D.B.; Chong, B.H.; Cooper, N.; Godeau, B.; Lechner, K.; Mazzucconi, M.G.; McMillan, R.; Sanz, M.A.; Imbach, P.; Blanchette, V.; Kühne, T.; Ruggeri, M.; George, J.N. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood, 2009, 113(11), 2386-2393.
[http://dx.doi.org/10.1182/blood-2008-07-162503] [PMID: 19005182]
[2]
Provan, D.; Arnold, D.M.; Bussel, J.B.; Chong, B.H.; Cooper, N.; Gernsheimer, T.; Ghanima, W.; Godeau, B. Gonzá-lez-López, T.J.; Grainger, J.; Hou, M.; Kruse, C.; McDonald, V.; Michel, M.; Newland, A.C.; Pavord, S.; Rodeghiero, F.; Scully, M.; Tomiyama, Y.; Wong, R.S.; Zaja, F. and Kuter D.J. Updated international consensus report on the in-vestigation and management of primary immune thrombocytopenia. Blood Adv., 2019, 3(22), 3780-3817.
[http://dx.doi.org/10.1182/bloodadvances.2019000812] [PMID: 31770441]
[3]
D’Orazio, J.A.; Neely, J.; Farhoudi, N. ITP in children: pathophysiology and current treatment approaches. J. Pediatr. Hematol. Oncol., 2013, 35(1), 1-13.
[http://dx.doi.org/10.1097/MPH.0b013e318271f457] [PMID: 23073045]
[4]
Sarpatwari, A.; Provan, D.; Erqou, S.; Sobnack, R.; David Tai, F.W.; Newland, A.C. Autologous 111 in-labelled platelet sequestration studies in patients with primary immune thrombocytopenia (ITP) prior to splenectomy: a report from the United Kingdom ITP registry. Br. J. Haematol., 2010, 151(5), 477-487.
[http://dx.doi.org/10.1111/j.1365-2141.2010.08377.x] [PMID: 20950403]
[5]
Del Vecchio, G.C.; Giordano, P.; Tesse, R.; Piacente, L.; Altomare, M.; De Mattia, D. Clinical significance of serum cytokine levels and thrombopoietic markers in childhood idiopathic thrombocytopenic purpura. Blood Transfus., 2012, 10(2), 194-199.
[PMID: 22153687]
[6]
Cecinati, V.; Principi, N.; Brescia, L.; Giordano, P.; Esposito, S. Vaccine administration and the development of immune thrombocytopenic purpura in children. Hum. Vaccin. Immunother., 2013, 9(5), 1158-1162.
[http://dx.doi.org/10.4161/hv.23601] [PMID: 23324619]
[7]
Giordano, P.; Urbano, F.; Lassandro, G.; Bianchi, F.P.; Tolva, A.; Saracco, P.; Russo, G.; Notarangelo, L.D.; Gabelli, M.; Cesaro, S.; Wasniewska, M.; Faienza, M.F. Role of antithyroid autoimmunity as a predictive biomarker of chronic immune thrombocytopenia. Pediatr. Blood Cancer, 2019, 66(1)e27452
[http://dx.doi.org/10.1002/pbc.27452] [PMID: 30270575]
[8]
Giordano, P.; Cascioli, S.; Lassandro, G.; Marcellini, V.; Cardinale, F.; Valente, F.; Locatelli, F.; Carsetti, R. B-cell hyperfunction in children with immune thrombocytopenic purpura persists after splenectomy. Pediatr. Res., 2016, 79(2), 262-270.
[http://dx.doi.org/10.1038/pr.2015.211] [PMID: 26492283]
[9]
Olsson, B.; Andersson, P.O.; Jernås, M.; Jacobsson, S.; Carlsson, B.; Carlsson, L.M.; Wadenvik, H. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat. Med., 2003, 9(9), 1123-1124.
[http://dx.doi.org/10.1038/nm921] [PMID: 12937414]
[10]
Zufferey, A.; Kapur, R.; Semple, J.W. Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP). J. Clin. Med., 2017, 6(2)E16
[http://dx.doi.org/10.3390/jcm6020016] [PMID: 28208757]
[11]
Khodadi, E.; Asnafi, A.A.; Shahrabi, S.; Shahjahani, M.; Saki, N. Bone marrow niche in immune thrombocytopenia: a focus on megakaryopoiesis. Ann. Hematol., 2016, 95(11), 1765-1776.
[http://dx.doi.org/10.1007/s00277-016-2703-1] [PMID: 27236577]
[12]
Kuter, D.J.; Gernsheimer, T.B. Thrombopoietin and platelet production in chronic immune thrombocytopenia. Hematol. Oncol. Clin. North Am., 2009, 23(6), 1193-1211.
[http://dx.doi.org/10.1016/j.hoc.2009.09.001] [PMID: 19932428]
[13]
Kurata, Y.; Fujimura, K.; Kuwana, M.; Tomiyama, Y.; Murata, M. Epidemiology of primary immune thrombocytopenia in children and adults in Japan: a population-based study and literature review. Int. J. Hematol., 2011, 93(3), 329-335.
[http://dx.doi.org/10.1007/s12185-011-0791-1] [PMID: 21347644]
[14]
Moulis, G.; Palmaro, A.; Montastruc, J.L.; Godeau, B.; Lapeyre-Mestre, M.; Sailler, L. Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France. Blood, 2014, 124(22), 3308-3315.
[http://dx.doi.org/10.1182/blood-2014-05-578336] [PMID: 25305203]
[15]
Hung, G.Y.; Lee, C.Y.; Yen, H.J.; Lin, L.Y.; Horng, J.L. Incidence of immune thrombocytopenia in Taiwan: a nationwide population-based study. Transfusion, 2018, 58(11), 2712-2719.
[http://dx.doi.org/10.1111/trf.14915] [PMID: 30311951]
[16]
Lee, J.Y.; Lee, J.H.; Lee, H.; Kang, B.; Kim, J.W.; Kim, S.H.; Lee, J.O.; Kim, J.W.; Kim, Y.J.; Lee, K.W.; Kim, J.H.; Choi, H.S.; Lee, J.S.; Bang, S.M. Epidemiology and management of primary immune thrombocytopenia: a nationwide population-based study in Korea. Thromb. Res., 2017, 155, 86-91.
[http://dx.doi.org/10.1016/j.thromres.2017.05.010] [PMID: 28525829]
[17]
Labarque, V.; Van Geet, C. Clinical practice: immune thrombocytopenia in paediatrics. Eur. J. Pediatr., 2014, 173(2), 163-172.
[http://dx.doi.org/10.1007/s00431-013-2254-6] [PMID: 24390128]
[18]
Faki Osman, M.E. Childhood immune thrombocytopenia: clinical presentation and management. Sudan. J. Paediatr., 2012, 12(1), 27-39.
[PMID: 27493327]
[19]
Arnold, D.M. Bleeding complications in immune thrombocytopenia. Hematology (Am. Soc. Hematol. Educ. Program), 2015, 2015, 237-242.
[http://dx.doi.org/10.1182/asheducation-2015.1.237] [PMID: 26637728]
[20]
Neunert, C.; Noroozi, N.; Norman, G.; Buchanan, G.R.; Goy, J.; Nazi, I.; Kelton, J.G.; Arnold, D.M. Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review. J. Thromb. Haemost., 2015, 13(3), 457-464.
[http://dx.doi.org/10.1111/jth.12813] [PMID: 25495497]
[21]
Tarantino, M.D.; Danese, M.; Klaassen, R.J.; Duryea, J.; Eisen, M.; Bussel, J. Hospitalizations in pediatric patients with immune thrombocytopenia in the United States. Platelets, 2016, 27(5), 472-478.
[http://dx.doi.org/10.3109/09537104.2016.1143923] [PMID: 26941022]
[22]
Choudhary, D.R.; Naithani, R.; Mahapatra, M.; Kumar, R.; Mishra, P.; Saxena, R. Intracranial hemorrhage in childhood immune thrombocytopenic purpura. Pediatr. Blood Cancer, 2009, 52(4), 529-531.
[http://dx.doi.org/10.1002/pbc.21728] [PMID: 19058201]
[23]
Kühne, T. Diagnosis and management of immune thrombocytopenia in childhood. Hamostaseologie, 2017, 37(1), 36-44.
[http://dx.doi.org/10.5482/HAMO-16-06-0017] [PMID: 27699328]
[24]
Consolini, R.; Costagliola, G.; Spatafora, D. The centenary of immune thrombocytopenia-part 2: revising diagnostic and therapeutic approach. Front Pediatr., 2017, 5, 179.
[http://dx.doi.org/10.3389/fped.2017.00179] [PMID: 28871277]
[25]
Del Vecchio, G.C.; De Santis, A.; Giordano, P.; Amendola, G.; Baronci, C.; Del Principe, D.; Nobili, B.; Jankovic, M.; Ramenghi, U.; Russo, G.; Zecca, M.; De Mattia, D. AIEOP ITP study group. Management of acute childhood idiopathic thrombocytopenic purpura according to AIEOP consensus guidelines: assessment of Italian experience. Acta Haematol., 2008, 119(1), 1-7.
[http://dx.doi.org/10.1159/000112837] [PMID: 18176072]
[26]
De Mattia, D.; Del Vecchio, G.C.; Russo, G.; De Santis, A.; Ramenghi, U.; Notarangelo, L.; Jankovic, M.; Molinari, A.C.; Zecca, M.; Nobili, B.; Giordano, P. AIEOP-ITP study group. Management of chronic childhood immune thrombocytopenic purpura: AIEOP consensus guidelines. Acta Haematol., 2010, 123(2), 96-109.
[http://dx.doi.org/10.1159/000268855] [PMID: 20029174]
[27]
Giordano, P.; Lassandro, G.; Giona, F.; Jankovic, M.; Nardi, M.; Nobili, B.; Notarangelo, L.D.; Russo, G.; Mackensen, Sv. ITP-QoL questionnaire for children with immune thrombocytopenia: Italian version validation’s. Pediatr. Hematol. Oncol., 2014, 31(6), 534-547.
[http://dx.doi.org/10.3109/08880018.2014.915443] [PMID: 24852656]
[28]
Bussel, J.B.; de Miguel, P.G.; Despotovic, J.M.; Grainger, J.D.; Sevilla, J.; Blanchette, V.S.; Krishnamurti, L.; Connor, P.; David, M.; Boayue, K.B.; Matthews, D.C.; Lambert, M.P.; Marcello, L.M.; Iyengar, M.; Chan, G.W.; Chagin, K.D.; Theodore, D.; Bailey, C.K.; Bakshi, K.K. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. Lancet Haematol., 2015, 2(8), e315-e325.
[http://dx.doi.org/10.1016/S2352-3026(15)00114-3] [PMID: 26688484]
[29]
Grainger, J.D.; Locatelli, F.; Chotsampancharoen, T.; Donyush, E.; Pongtanakul, B.; Komvilaisak, P.; Sosothikul, D.; Drelichman, G.; Sirachainan, N.; Holzhauer, S.; Lebedev, V.; Lemons, R.; Pospisilova, D.; Ramenghi, U.; Bussel, J.B.; Bakshi, K.K.; Iyengar, M.; Chan, G.W.; Chagin, K.D.; Theodore, D.; Marcello, L.M.; Bailey, C.K. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial. Lancet, 2015, 386(10004), 1649-1658.
[http://dx.doi.org/10.1016/S0140-6736(15)61107-2] [PMID: 26231455]
[30]
Santoro, N.; Colombini, A.; Silvestri, D.; Grassi, M.; Giordano, P.; Parasole, R.; Barisone, E.; Caruso, R.; Conter, V.; Valsecchi, M.G.; Masera, G.; Rizzari, C. Screening for coagulopathy and identification of children with acute lymphoblastic leukemia at a higher risk of symptomatic venous thrombosis: an AIEOP experience. J. Pediatr. Hematol. Oncol., 2013, 35(5), 348-355.
[http://dx.doi.org/10.1097/MPH.0b013e31828dc614] [PMID: 23619106]
[31]
Bussel, J.B.; Buchanan, G.R.; Nugent, D.J.; Gnarra, D.J.; Bomgaars, L.R.; Blanchette, V.S.; Wang, Y.M.; Nie, K.; Jun, S. A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. Blood, 2011, 118(1), 28-36.
[http://dx.doi.org/10.1182/blood-2010-10-313908] [PMID: 21502541]
[32]
Li, C.; Zheng, L. The pharmacology and clinical application of thrombopoietin receptor agonists. Int. J. Hematol., 2014, 100(6), 529-539.
[http://dx.doi.org/10.1007/s12185-014-1660-5] [PMID: 25230815]
[33]
Zhang, Y.; Kolesar, J.M. Eltrombopag: an oral thrombopoietin receptor agonist for the treatment of idiopathic thrombocytopenic purpura. Clin. Ther., 2011, 33(11), 1560-1576.
[http://dx.doi.org/10.1016/j.clinthera.2011.10.004] [PMID: 22054810]
[34]
Corman, S.L.; Mohammad, R.A. Eltrombopag: a novel oral thrombopoietin receptor agonist. Ann. Pharmacother., 2010, 44(6), 1072-1079.
[http://dx.doi.org/10.1345/aph.1P042] [PMID: 20460556]
[35]
Wang, B.; Nichol, J.L.; Sullivan, J.T. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin. Pharmacol. Ther., 2004, 76(6), 628-638.
[http://dx.doi.org/10.1016/j.clpt.2004.08.010] [PMID: 15592334]
[36]
Bussel, J.B.; Kuter, D.J.; George, J.N.; McMillan, R.; Aledort, L.M.; Conklin, G.T.; Lichtin, A.E.; Lyons, R.M.; Nieva, J.; Wasser, J.S.; Wiznitzer, I.; Kelly, R.; Chen, C.F.; Nichol, J.L. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N. Engl. J. Med., 2006, 355(16), 1672-1681.
[http://dx.doi.org/10.1056/NEJMoa054626] [PMID: 17050891]
[37]
Kuter, D.J. The biology of thrombopoietin and thrombopoietin receptor agonists. Int. J. Hematol., 2013, 98(1), 10-23.
[http://dx.doi.org/10.1007/s12185-013-1382-0] [PMID: 23821332]
[38]
Qu, M.M.; Liu, X.N.; Liu, X.G.; Feng, Q.; Liu, Y.; Zhang, X.; Liu, S.; Zhang, L.; Li, G.S.; Zhu, Y.Y.; Lv, M.Y.; Peng, J.; Hou, M. Cytokine changes in response to TPO receptor agonist treatment in primary immune thrombocytopenia. Cytokine, 2017, 92, 110-117.
[http://dx.doi.org/10.1016/j.cyto.2017.01.013] [PMID: 28142109]
[39]
Li, X.; Zhong, H.; Bao, W.; Boulad, N.; Evangelista, J.; Haider, M.A.; Bussel, J.; Yazdanbakhsh, K. Defective regulatory B-cell compartment in patients with immune thrombocytopenia. Blood, 2012, 120(16), 3318-3325.
[http://dx.doi.org/10.1182/blood-2012-05-432575] [PMID: 22859611]
[40]
Brynes, R.; Orazi, A.; Theodore, D.; Burgess, P.; Bailey, C.K.; Thein, M.M.; Bakshi, K.K. Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia: data from the EXTEND study. Am. J. Hematol., 2015, 90(7), 598-601.
[http://dx.doi.org/10.1002/ajh.24011] [PMID: 25801698]
[41]
Ghanima, W.; Junker, P.; Hasselbalch, H.C.; Boiocchi, L.; Geyer, J.T.; Feng, X.; Gudbrandsdottir, S.; Orazi, A.; Bussel, J.B. Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents. Br. J. Haematol., 2011, 155(2), 248-255.
[http://dx.doi.org/10.1111/j.1365-2141.2011.08845.x] [PMID: 21902682]
[42]
Ghanima, W.; Geyer, J.T.; Lee, C.S.; Boiocchi, L.; Imahiyerobo, A.A.; Orazi, A.; Bussel, J.B. Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-up. Haematologica, 2014, 99(5), 937-944.
[http://dx.doi.org/10.3324/haematol.2013.098921] [PMID: 24463212]
[43]
Ehrlich, L.A.; Kwitkowski, V.E.; Reaman, G.; Ko, C.W.; Nie, L.; Pazdur, R.; Farrell, A.T.U.S. food and drug administration approval summary: Eltrombopag for the treatment of pediatric patients with chronic immune (idiopathic) thrombocytopenia. Pediatr. Blood Cancer, 2017, 64(12)e26657
[http://dx.doi.org/10.1002/pbc.26657] [PMID: 28627134]
[44]
Kim, T.O.; Despotovic, J.; Lambert, M.P. Eltrombopag for use in children with immune thrombocytopenia. Blood Adv., 2018, 2(4), 454-461.
[http://dx.doi.org/10.1182/bloodadvances.2017010660] [PMID: 29487060]
[45]
Grainger, J.D.; Thind, S. A practical guide to the use of eltrombopag in children with chronic immune thrombocytopenia. Pediatr. Hematol. Oncol., 2017, 34(2), 73-89.
[http://dx.doi.org/10.1080/08880018.2017.1313918] [PMID: 28537785]
[46]
Giordano, P.; Lassandro, G.; Barone, A.; Cesaro, S.; Fotzi, I.; Giona, F.; Ladogana, S.; Miano, M.; Marzollo, A.; Nardi, M.; Notarangelo, L.D.; Pession, A.; Ruggiero, A.; Russo, G.; Saracco, P.; Spinelli, M.; Tolva, A.; Tornesello, A.; Palladino, V.; Del Vecchio, G.C. Use of Eltrombopag in children with chronic immune thrombocytopenia (ITP): a real life retrospective multicenter experience of the Italian association of pediatric hematology and oncology (AIEOP). Front. Med. (Lausanne), 2020, 7, 66.
[http://dx.doi.org/10.3389/fmed.2020.00066] [PMID: 32181255]
[47]
Elalfy, M.S.; Abdelmaksoud, A.A.; Eltonbary, K.Y. Romiplostim in children with chronic refractory ITP: randomized placebo controlled study. Ann. Hematol., 2011, 90(11), 1341-1344.
[http://dx.doi.org/10.1007/s00277-011-1172-9] [PMID: 21318572]
[48]
Tarantino, M.D.; Bussel, J.B.; Blanchette, V.S.; Despotovic, J.; Bennett, C.; Raj, A.; Williams, B.; Beam, D.; Morales, J.; Rose, M.J.; Carpenter, N.; Nie, K.; Eisen, M. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study. Lancet, 2016, 388(10039), 45-54.
[http://dx.doi.org/10.1016/S0140-6736(16)00279-8] [PMID: 27103127]
[49]
Escudero Vilaplana, V.; Aragonés, J.H.; Fernández-Llamazares, C.M.; Bieler, C.B.; Rodríguez, S.M.; Sáez, M.S. Use of romiplostim for primary immune thrombocytopenia in children. Pediatr. Hematol. Oncol., 2012, 29(2), 197-205.
[http://dx.doi.org/10.3109/08880018.2011.629401] [PMID: 22376020]
[50]
Mokhtar, G.M.; Tantawy, A.A.; El Sherif, N.H. Romiplostim therapy in children with unresponsive chronic immune thrombocytopenia. Platelets, 2012, 23(4), 264-273.
[http://dx.doi.org/10.3109/09537104.2011.619601] [PMID: 22471399]
[51]
Seidel, M.G.; Urban, C.; Sipurzynski, J.; Beham-Schmid, C.; Lackner, H.; Benesch, M. High response rate but short-term effect of romiplostim in paediatric refractory chronic immune thrombocytopenia. Br. J. Haematol., 2014, 165(3), 419-421.
[http://dx.doi.org/10.1111/bjh.12766] [PMID: 24484542]
[52]
Pasquet, M.; Aladjidi, N.; Guiton, C.; Courcoux, M.F.; Munzer, M.; Auvrignon, A.; Lutz, P.; Ducassou, S.; Leroy, G.; Munzer, C.; Leverger, G. Centre de Référence National des Cytopénies Auto-immunes de l’Enfant (CEREVANCE). Romiplostim in children with chronic immune thrombocytopenia (ITP): the French experience. Br. J. Haematol., 2014, 164(2), 266-271.
[http://dx.doi.org/10.1111/bjh.12609] [PMID: 24152194]
[53]
Bussel, J.B.; Hsieh, L.; Buchanan, G.R.; Stine, K.; Kalpatthi, R.; Gnarra, D.J.; Ho, R.H.; Nie, K.; Eisen, M. Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP). Pediatr. Blood Cancer, 2015, 62(2), 208-213.
[http://dx.doi.org/10.1002/pbc.25136] [PMID: 25345874]
[54]
Neunert, C.E.; Rose, M.J. Romiplostim for the management of pediatric immune thrombocytopenia: drug development and current practice. Blood Adv., 2019, 3(12), 1907-1915.
[http://dx.doi.org/10.1182/bloodadvances.2019000279] [PMID: 31239245]
[55]
Vishnu, P.; Aboulafia, D.M. Long-term safety and efficacy of romiplostim for treatment of immune thrombocytopenia. J. Blood Med., 2016, 7, 99-106.
[PMID: 27307776]
[56]
Buchbinder, D.; Nugent, D.; Hsieh, L. Spotlight on romiplostim in the treatment of children with chronic immune thrombocytopenia: design, development, and potential place in therapy. Drug Des. Devel. Ther., 2017, 11, 1055-1063.
[http://dx.doi.org/10.2147/DDDT.S113191] [PMID: 28408804]
[57]
Tarantino, M.D.; Bussel, J.B.; Blanchette, V.S.; Beam, D.; Roy, J.; Despotovic, J.; Raj, A.; Carpenter, N.; Mehta, B.; Eisen, M. Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia. Haematologica, 2019, 104(11), 2283-2291.
[http://dx.doi.org/10.3324/haematol.2018.202283] [PMID: 30846500]
[58]
Marano, M.; Serafinelli, J.; Cairoli, S.; Martinelli, D.; Pisani, M.; Palumbo, G.; Cefalo, M.G.; Cecchetti, C.; Di Nardo, M.; Falvella, F.S.; Goffredo, B.M. Eltrombopag-induced acute liver failure in a pediatric patient: a pharmacokinetic and pharmacogenetic analysis. Ther. Drug Monit., 2018, 40(4), 386-388.
[http://dx.doi.org/10.1097/FTD.0000000000000522] [PMID: 29683873]
[59]
Lambert, M.P.; Witmer, C.M.; Kwiatkowski, J.L. Therapy induced iron deficiency in children treated with eltrombopag for immune thrombocytopenia. Am. J. Hematol., 2017, 92(6), E88-E91.
[http://dx.doi.org/10.1002/ajh.24705] [PMID: 28240793]
[60]
Roth, M.; Will, B.; Simkin, G.; Narayanagari, S.; Barreyro, L.; Bartholdy, B.; Tamari, R.; Mitsiades, C.S.; Verma, A.; Steidl, U. Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. Blood, 2012, 120(2), 386-394.
[http://dx.doi.org/10.1182/blood-2011-12-399667] [PMID: 22627766]
[61]
Will, B.; Kawahara, M.; Luciano, J.P.; Bruns, I.; Parekh, S.; Erickson-Miller, C.L.; Aivado, M.A.; Verma, A.; Steidl, U. Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. Blood, 2009, 114(18), 3899-3908.
[http://dx.doi.org/10.1182/blood-2009-04-219493] [PMID: 19710504]
[62]
Mitchell, W.B.; Bussel, J.B. Thrombopoietin receptor agonists: a critical review. Semin. Hematol., 2015, 52(1), 46-52.
[http://dx.doi.org/10.1053/j.seminhematol.2014.11.001] [PMID: 25578419]
[63]
Ramaswamy, K.; Hsieh, L.; Leven, E.; Thompson, M.V.; Nugent, D.; Bussel, J.B. Thrombopoietic agents for the treatment of persistent and chronic immune thrombocytopenia in children. J. Pediatr., 2014, 165(3), 600-5.e4.
[http://dx.doi.org/10.1016/j.jpeds.2014.03.060] [PMID: 24857517]
[64]
Neunert, C.; Despotovic, J.; Haley, K.; Lambert, M.P.; Nottage, K.; Shimano, K.; Bennett, C.; Klaassen, R.; Stine, K.; Thompson, A.; Pastore, Y.; Brown, T.; Forbes, P.W.; Grace, R.F. Pediatric ITP Consortium of North America (ICON). Thrombopoietin receptor agonist use in children: data from the Pediatric ITP Consortium of North America ICON2 study. Pediatr. Blood Cancer, 2016, 63(8), 1407-1413.
[http://dx.doi.org/10.1002/pbc.26003] [PMID: 27135461]
[65]
Grace, R.F.; Shimano, K.A.; Bhat, R.; Neunert, C.; Bussel, J.B.; Klaassen, R.J.; Lambert, M.P.; Rothman, J.A.; Breakey, V.R.; Hege, K.; Bennett, C.M.; Rose, M.J.; Haley, K.M.; Buchanan, G.R.; Geddis, A.; Lorenzana, A.; Jeng, M.; Pastore, Y.D.; Crary, S.E.; Neier, M.; Neufeld, E.J.; Neu, N.; Forbes, P.W.; Despotovic, J.M. Second-line treatments in children with immune thrombocytopenia: effect on platelet count and patient-centered outcomes. Am. J. Hematol., 2019, 94(7), 741-750.
[http://dx.doi.org/10.1002/ajh.25479] [PMID: 30945320]
[66]
Zhang, J.; Liang, Y.; Ai, Y.; Xie, J.; Li, Y.; Zheng, W. Thrombopoietin-receptor agonists for children with immune thrombocytopenia: a systematic review. Expert Opin. Pharmacother., 2017, 18(15), 1543-1551.
[http://dx.doi.org/10.1080/14656566.2017.1373091] [PMID: 28845713]
[67]
Guo, J.C.; Zheng, Y.; Chen, H.T.; Zhou, H.; Huang, X.H.; Zhong, L.P.; Zhou, H.B.; Huang, Y.; Xie, D.L.; Lou, Y.L. Efficacy and safety of thrombopoietin receptor agonists in children with chronic immune thrombocytopenia: a meta-analysis. Oncotarget, 2017, 9(6), 7112-7125.
[PMID: 29467954]
[68]
Tumaini Massaro, J.; Chen, Y.; Ke, Z. Efficacy and safety of thrombopoietin receptor agonists in children with chronic immune thrombocytopenic purpura: meta-analysis. Platelets, 2019, 30(7), 828-835.
[http://dx.doi.org/10.1080/09537104.2019.1572873] [PMID: 30810479]
[69]
Tremblay, G.; Dolph, M.; Bhor, M.; Said, Q.; Roy, A.; Elliott, B.; Briggs, A. Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopenia. Clinicoecon. Outcomes Res., 2018, 10, 715-721.
[http://dx.doi.org/10.2147/CEOR.S177338] [PMID: 30464564]
[70]
Flores, A.; Klaassen, R.J.; Buchanan, G.R.; Neunert, C.E. Patterns and influences in health-related quality of life in children with immune thrombocytopenia: A study from the Dallas ITP Cohort. Pediatr. Blood Cancer, 2017, 64(8)
[http://dx.doi.org/10.1002/pbc.26405] [PMID: 28111877]
[71]
Zhang, H.; Wang, L.; Quan, M.; Huang, J.; Wu, P.; Lu, Q.; Fang, Y. Health-related quality of life in children with chronic immune thrombocytopenia in China. Health Qual. Life Outcomes, 2016, 14, 45.
[http://dx.doi.org/10.1186/s12955-016-0445-3] [PMID: 26979950]
[72]
Mokhtar, G.M.; Farid, S.M.; Shaker, N.M.; Farrag, K.E. Health-related quality of life of Egyptian children with immune thrombocytopenia and their parents. J. Pediatr. Hematol. Oncol., 2014, 36(3), 194-199.
[http://dx.doi.org/10.1097/MPH.0000000000000023] [PMID: 24322497]
[73]
Giordano, P.; Lassandro, G.; di Meo, N.A.; Palladino, V.; Lovrencic, B.; Spinelli, M.; Reale, L.; Jankovic, M. A narrative approach to describe QoL in children with chronic ITP. Front Pediatr., 2019, 7, 163.
[http://dx.doi.org/10.3389/fped.2019.00163] [PMID: 31134165]
[74]
Lassandro, G.; Palmieri, V.V.; Palladino, V.; Accettura, D.; Valente, R.; Giordano, P. Sport and children with immune thrombocytopenia: never give up. Curr. Sports Med. Rep., 2019, 18(9), 317-318.
[http://dx.doi.org/10.1249/JSR.0000000000000631] [PMID: 31503041]
[75]
Mathias, S.D.; Li, X.; Eisen, M.; Carpenter, N.; Crosby, R.D.; Blanchette, V.S. A phase 3, randomized, double-blind, placebo-controlled study to determine the effect of Romiplostim on health-related quality of life in children with primary immune thrombocytopenia and associated burden in their parents. Pediatr. Blood Cancer, 2016, 63(7), 1232-1237.
[http://dx.doi.org/10.1002/pbc.25984] [PMID: 27037553]
[76]
Grainger, J.D.; Blanchette, V.S.; Grotzinger, K.M.; Roy, A.; Bussel, J.B. Health-related quality of life in children with chronic immune thrombocytopenia treated with eltrombopag in the PETIT study. Br. J. Haematol., 2019, 185(1), 102-106.
[http://dx.doi.org/10.1111/bjh.15732] [PMID: 30592022]

Rights & Permissions Print Cite
Article Metrics
20
1
© 2024 Bentham Science Publishers | Privacy Policy